Serine

Serine

SCHEMBL1162408

NC(CO)C(=O)O.NC(CS)C(=O)O

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.80
SLC7A11 Q9UPY5 1/20 0.80
SLC1A1 P43005 4/20 0.48
ENPEP Q07075 6/20 0.44
SLC1A3 P43003 3/20 0.41
SLC1A2 P43004 3/20 0.41
GSR P00390 2/20 0.41
GRIK1 P39086 2/20 0.41
GRIK2 Q13002 2/20 0.41
GRM1 Q13255 2/20 0.41
GRM2 Q14416 2/20 0.41
CYP1A2 P05177 2/20 0.41
SLC7A5 Q01650 1/20 0.41
GRM8 O00222 1/20 0.41
GRM6 O15303 1/20 0.41
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GRM5 P41594 1/20 0.41
GRIA1 P42261 1/20 0.41
GRIA2 P42262 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Serine SCHEMBL17113867 1.00 PTGS1 (0.80) PTGS1SLC7A11SLC1A1ENPEPSLC1A3
Serine SCHEMBL27748272 1.00 PTGS1 (0.80) PTGS1SLC7A11SLC1A1ENPEPSLC1A3
Serine SCHEMBL26613653 1.00 PTGS1 (0.80) PTGS1SLC7A11SLC1A1ENPEPSLC1A3
Serine SCHEMBL1162414 1.00 PTGS1 (0.80) PTGS1SLC7A11SLC1A1ENPEPSLC1A3
Serine SCHEMBL17113864 1.00 PTGS1 (0.80) PTGS1SLC7A11SLC1A1ENPEPSLC1A3
Serine SCHEMBL9053725 0.95 PTGS1 (0.73) PTGS1SLC7A11SLC1A1ENPEPSLC1A3
Serine SCHEMBL9053744 0.95 PTGS1 (0.73) PTGS1SLC7A11SLC1A1ENPEPSLC1A3
Serine SCHEMBL16058500 0.91 PTGS1 (0.67) PTGS1SLC7A11SLC1A1ENPEPSLC1A3
Serine SCHEMBL418635 0.91 PTGS1 (0.67) PTGS1SLC7A11SLC1A1ENPEPSLC1A3
Serine SCHEMBL21752129 0.91 PTGS1 (0.67) PTGS1SLC7A11SLC1A1ENPEPSLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116135229-A Application of hypocrellin-containing derivative with both peri-position and 2-position being simultaneously substituted in preparation of photodynamic anti-tumor drugs 中国科学院理化技术研究所 2023-05-19 CN claimed
CN-112638937-A Pegylated tetanus neurotoxin and hypotonia treatment 斯诺雷托克斯私人有限公司 2021-04-09 CN claimed
US-20190030124-A1 USE OF DERMCIDIN IN STERILE INFLAMMATORY CONDITIONS THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) 2019-01-31 US claimed
CN-107172880-A Modified antibodies comprising a modified IgG2 domain that elicit agonistic or antagonistic properties and uses thereof 癌症研究技术有限公司 2017-09-15 CN claimed
WO-2017070421-A1 USE OF DERMCIDIN IN STERILE INFLAMMATORY CONDITIONS THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) 2017-04-27 WO claimed
US-20130203129-A1 POLYPEPTIDES AND BIOSYNTHETIC PATHWAYS FOR THE PRODUCTION OF MONATIN AND ITS PRECURSORS CARGILL, INCORPORATED (US) 2013-08-08 US claimed
EP-1503985-B1 POLYPEPTIDES AND BIOSYNTHETIC PATHWAYS CARGILL INC (US) 2010-12-15 EP claimed
JP-56166285-A None JP disclosed
WO-2024092274-A2 ENDOCYTIC AGENTS BIOVENTURES, LLC (US) 2024-05-02 WO disclosed
US-20220228185-A1 Recombinant Production of Steviol Glycosides EVOLVA SA (CH) 2022-07-21 US disclosed
US-11266716-B2 Use of dermcidin in sterile inflammatory conditions THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2022-03-08 US disclosed
US-11254738-B2 Synthetic antibodies against VEGF and their uses THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO BANTING INSTITUTE (CA) 2022-02-22 US disclosed
US-20210228729-A1 LGALS3BP ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER MEDIAPHARMA S.R.L. (IT) 2021-07-29 US disclosed
EP-0900276-A1 NOVEL CYCLIN-SELECTIVE UBIQUITIN CARRIER POLYPEPTIDES PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1999-03-10 EP disclosed
US-5770560-A TREATING REDUCED HEMOGLOBIN OXYGEN AFFINITY IN MAMMALS Fischer, James J. (US) 1998-06-23 US disclosed
WO-1997037027-A1 NOVEL CYCLIN-SELECTIVE UBIQUITIN CARRIER POLYPEPTIDES PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1997-10-09 WO disclosed
US-4863898-A Amino acid chelated compositions for delivery to specific biological tissue sites ALBION INTERNATIONAL, INC. (US) 1989-09-05 US disclosed
JP-S56166285-A PREPARATION OF ANTIOXIDANT M S C:KK 1981-12-21 JP disclosed
US-4212945-A DIPEPTIDE SYNTHESIS FROM AN AMINE-PROTECTED AND FROM A CARBOXY-PROTECTED AMINO ACID, POLAR SOLVENT (ZAIDANHOJIN) SAGAMI CHEMICAL RESEARCH CENTER (JP) 1980-07-15 US disclosed
US-4212946-A DIPEPTIDE SYNTHESIS FROM AN AMINE-PROTECTED AND FROM A CARBOXY-PROTECTED AMINO ACID, SOLVENT TOYO SODA MANUFACTURING CO., LTD. (JP) 1980-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210228729-A1 LGALS3BP ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER LGALS3BP, LGALS3, LGALS4 PTGS1 4748/4885SLC7A11 2847/4885SLC1A1 1230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.